Literature DB >> 20180606

Deterioration of blood pressure control after discontinuation of a physician-pharmacist collaborative intervention.

Barry L Carter1, William R Doucette, Carrie L Franciscus, Gail Ardery, Karen M Kluesner, Elizabeth A Chrischilles.   

Abstract

STUDY
OBJECTIVE: To assess blood pressure control after discontinuation of a physician-pharmacist collaborative intervention.
DESIGN: Comparative analysis of data of the patients who received the intervention versus a control group from a prospective, cluster-randomized, 9-month efficacy trial and the same patients' data 18 and 27 months after completion of the trial, abstracted from their medical records.
SETTING: Five primary care medical offices operated by a university health system. PATIENTS: One hundred four patients with hypertension; 65 were in the intervention group, and 39 were in the control group.
MEASUREMENTS AND MAIN RESULTS: In the prospective study, patients were randomized to receive a physician-pharmacist collaborative intervention to improve blood pressure control or to the control group. Systolic and diastolic blood pressures were measured by a research nurse at baseline and at the end of the study (9 mo later). In the current study, data were abstracted for blood pressure and blood pressure control at 18 and 27 months (9 and 18 mo, respectively, after discontinuation of the study). At baseline, mean +/- SD systolic blood pressure was 152.5 +/- 9.5 and 150.1 +/- 9.6 mm Hg in the intervention and control groups, respectively (p=0.22). At 9 months, systolic blood pressure decreased to 124.5 +/- 10.7 and 132.0 +/- 15.1 mm Hg (p=0.0038 between groups), and blood pressure was controlled in 78.5% and 48.7% (p=0.0017) of patients in the intervention and control groups, respectively. By 18 months, systolic blood pressure had deteriorated to 131.0 +/- 12.2 and 143.3 +/- 17.5 mm Hg (p<0.001), and blood pressure control rates decreased to 53.9% and 30.8% (p=0.02). By 27 months, systolic blood pressure was 131.3 +/- 13.0 and 141.2 +/- 15.8 mm Hg (p=0.0008), and blood pressure control was 55.4% and 35.9% (p=0.05).
CONCLUSION: A sustained positive effect on blood pressure control was noted up to 18 months after discontinuation of a physician-pharmacist collaborative intervention, when compared with a control group. Blood pressure control did deteriorate at a similar rate in both the intervention and control groups, but the percentage of patients with controlled blood pressure remained significantly higher in the intervention group. These results suggest that continued interventions by pharmacists may be necessary to maintain high rates of blood pressure control, especially in those patients whose blood pressure begins to increase.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180606      PMCID: PMC2882166          DOI: 10.1592/phco.30.3.228

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  23 in total

Review 1.  Measuring adherence to practice guidelines for the management of hypertension: an evaluation of the literature.

Authors:  Jessica L Milchak; Barry L Carter; Paul A James; Gail Ardery
Journal:  Hypertension       Date:  2004-09-20       Impact factor: 10.190

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  The effect of clinical pharmacy services on patients with essential hypertension.

Authors:  J M McKenney; J M Slining; H R Henderson; D Devins; M Barr
Journal:  Circulation       Date:  1973-11       Impact factor: 29.690

4.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

5.  Physician-pharmacist comanagement of hypertension: a randomized, comparative trial.

Authors:  Jeff E Borenstein; Geneen Graber; Emmanuel Saltiel; Joel Wallace; Seonyoung Ryu; Jackson Archi; Stephen Deutsch; Scott R Weingarten
Journal:  Pharmacotherapy       Date:  2003-02       Impact factor: 4.705

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

7.  Sustained improvement in drug documentation, compliance, and disease control. A four-year analysis of an ambulatory care model.

Authors:  C A Bond; R Monson
Journal:  Arch Intern Med       Date:  1984-06

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  Improving blood pressure control in a pharmacist-managed hypertension clinic.

Authors:  Eva M Vivian
Journal:  Pharmacotherapy       Date:  2002-12       Impact factor: 4.705

Review 10.  The potency of team-based care interventions for hypertension: a meta-analysis.

Authors:  Barry L Carter; Meaghan Rogers; Jeanette Daly; Shimin Zheng; Paul A James
Journal:  Arch Intern Med       Date:  2009-10-26
View more
  19 in total

1.  2011 Canadian Hypertension Education Program recommendations: an annual update.

Authors:  Norm Campbell
Journal:  Can Fam Physician       Date:  2011-12       Impact factor: 3.275

2.  Sustained blood pressure control following discontinuation of a pharmacist intervention.

Authors:  Danielle M Wentzlaff; Barry L Carter; Gail Ardery; Carrie L Franciscus; William R Doucette; Elizabeth A Chrischilles; Kurt A Rosenkrans; Lucinda M Buys
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-03-18       Impact factor: 3.738

Review 3.  Educational strategies to enable expansion of pharmacogenomics-based care.

Authors:  Kristin Wiisanen Weitzel; Christina L Aquilante; Samuel Johnson; David F Kisor; Philip E Empey
Journal:  Am J Health Syst Pharm       Date:  2016-12-01       Impact factor: 2.637

4.  Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control.

Authors:  Barry L Carter; Christopher S Coffey; Gail Ardery; Liz Uribe; Dixie Ecklund; Paul James; Brent Egan; Mark Vander Weg; Elizabeth Chrischilles; Thomas Vaughn
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-03-24

5.  Effect of self-efficacy and social support on adherence to antihypertensive drugs.

Authors:  Thomas J Criswell; Cynthia A Weber; Yinghui Xu; Barry L Carter
Journal:  Pharmacotherapy       Date:  2010-05       Impact factor: 4.705

6.  Blood pressure 1 year after completion of web-based pharmacist care.

Authors:  Beverly B Green; Melissa L Anderson; James D Ralston; Sheryl L Catz; Andrea J Cook
Journal:  JAMA Intern Med       Date:  2013-07-08       Impact factor: 21.873

7.  Characteristics of diabetic patients associated with achieving and maintaining blood pressure targets in the Adherence and Intensification of Medications program.

Authors:  Mandi L Klamerus; Eve A Kerr; Hayden B Bosworth; Julie A Schmittdiel; Michele Heisler
Journal:  Chronic Illn       Date:  2013-07-26

Review 8.  Interventions to Improve Medication Adherence in Hypertensive Patients: Systematic Review and Meta-analysis.

Authors:  Vicki S Conn; Todd M Ruppar; Jo-Ana D Chase; Maithe Enriquez; Pamela S Cooper
Journal:  Curr Hypertens Rep       Date:  2015-12       Impact factor: 5.369

9.  Improving refill adherence and hypertension control in black patients: Wisconsin TEAM trial.

Authors:  Bonnie L Svarstad; Jane Morley Kotchen; Theresa I Shireman; Roger L Brown; Stephanie Y Crawford; Jeanine K Mount; Pamela A Palmer; Eva M Vivian; Dale A Wilson
Journal:  J Am Pharm Assoc (2003)       Date:  2013 Sep-Oct

10.  Incremental costs associated with physician and pharmacist collaboration to improve blood pressure control.

Authors:  Puttarin Kulchaitanaroaj; John M Brooks; Gail Ardery; Dana Newman; Barry L Carter
Journal:  Pharmacotherapy       Date:  2012-08       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.